Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 23

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 23
---
 of monetization transactions (including forward contracts and zero-cost collars). Our insider trading policy also prohibits our directors and officers from pledging company securities as collateral for a loan.

#### DELINQUENT SECTION 16(A) REPORTS
Under Section 16(a) of the Exchange Act and SEC rules, our directors, executive officers and beneficial owners of more than ten percent of any class of our equity securities are required to file periodic reports of their ownership, and changes in that ownership, with the SEC. Based solely on our review of these reports and representations of such reporting persons, we believe that in 2024 such reporting persons met all applicable Section 16(a) requirements, except for (i) a Form 4 for Hazel Hunt, Ph.D. reporting the exercise of stock options on January 8, 2024, which transaction was inadvertently reported late on a Form 4 that was filed on January 12, 2024 rather than the due date of January 10, 2024 and (ii) a Form 4 for Joseph K. Belanoff, M.D., reporting a gift to the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 on July 31, 2024, which transaction was subsequently reported on a Form 5, timely filed on February 14, 2025.

<div align='center'>14</div>

### EXECUTIVE COMPENSATION

### Compensation Discussion and Analysis
Our goal is to offer competitive compensation that rewards good short-term and long-term performance. Direct compensation consists of base salary, cash bonuses for the achievement of significant corporate goals, equity grants (which typically vest over four years) and sales commissions. The Compensation Committee has primary responsibility for designing and administering our compensation program.

This section discusses the principles underlying the compensation of the named executive officers included in the “Summary Compensation Table” and the factors that determined their compensation in 2024. Our named executive officers for 2024 were Joseph K. Belanoff, M.D., Chief Executive Officer and President; William Guyer, Pharm.D., Chief Development Officer; Sean Maduck, President, Corcept Endocrinology; Atabak Mokari, Chief Financial Officer and Treasurer; and Charles Robb, Chief Business Officer and Secretary.

#### Executive Summary
In 2024, we achieved significant clinical, commercial and financial goals:

• Expanded the scope of our commercial activities and increased revenue to $675.0 million in 202